Skip to main content
Full access
Letter to the Editor
Published Online: 1 November 2000

Testosterone Replacement Therapy for Anxiety

To the Editor: We report the case of a patient with previously undiagnosed hypogonadism whose anxiety symptoms improved after he received testosterone injections.
Mr. A, a 34-year-old man, was diagnosed with generalized anxiety disorder. His symptoms included mental exhaustion, irritability, insomnia, poor concentration, and decreased libido. He unsuccessfully tried relaxation techniques and biofeedback before beginning treatment with buspirone, 30 mg/day. After noticing improvement, he discontinued the medication after 2 months but resumed taking it 6 months later, when his anxiety returned.
A review of his medical record indicated that Mr. A had undergone a right orchiectomy several years earlier for an undescended testicle. Blood samples were taken for laboratory analysis. His testosterone level was 185 ng/dl (normal=241–827), and his free testosterone level was 8.9 pg/ml (normal=18–39). His luteinizing hormone level was 18.7 mIU/ml (normal=2–12), and his level of follicle-stimulating hormone was 31.4 mIU/ml (normal=1–8). The results of a physical examination and laboratory tests were within normal limits. Mr. A tapered his buspirone treatment and elected not to begin treatment with paroxetine.
Mr. A was referred to an endocrinologist, who ruled out occult malignancy and prescribed testosterone enanthate, 200 mg i.m. every 2 weeks. He reported resolution of his anxiety symptoms after 1 month. His concentration and libido increased, and he reported better orgasms. He tried to decrease the frequency of his injections but remained on the bimonthly schedule after feeling his anxiety symptoms returning. He has been on the regimen for more than 18 months and has experienced no side effects. This treatment plan may be continued indefinitely.
Contraindications to androgen replacement therapy include androgen-dependent cancers, such as prostate and male breast cancer, and benign prostatic hypertrophy when obstructive symptoms are present (1). A patient’s hematocrit and low-density/high-density lipoprotein ratio should be monitored, since testosterone can elevate these as well (1).
The literature supports a connection between hypogonadism and depression, as evidenced by untreated hypogonadal men scoring significantly higher in ratings of depression, anger, fatigue, and confusion than infertile and normal comparison men (2) and by the improvement of depressive symptoms after the administration of testosterone to hypogonadal men with depression refractory to selective serotonin reuptake inhibitors (3). Another study (4) has shown that testosterone replacement therapy decreases anger, nervousness, and irritability in hypogonadal men. The temporal connection between the improvement of Mr. A’s anxiety symptoms and replacement testosterone suggests an association between anxiety and hypogonadism. With this case report, we suggest including anxiety in the list of psychiatric manifestations of hypogonadism that improve with testosterone replacement therapy.

References

1.
Wang C, Swerdloff R: Androgen replacement therapy. Ann Med 1997; 29:365–370
2.
Burris A, Banks S, Carter S, Davidson J, Sherins R: A long-term, prospective study of the physiologic and behavioral effects of hormone replacement in untreated hypogonadal men. J Androl 1992; 13:297–304
3.
Seidman SN, Rabkin JG: Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J Affect Disord 1998; 48:157–161
4.
Wang C, Alexander G, Berman N, Salshian B, Davidson T, McDonald V, Steiner B, Hull L, Callegari C, Swerdloff RS: Testosterone replacement therapy improves mood in hypogonadal men: a clinical research center study. J Clin Endocrinol Metab 1996; 81:3578–3583

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 1884
PubMed: 11058497

History

Published online: 1 November 2000
Published in print: November 2000

Authors

Affiliations

ELSPETH CAMERON RITCHIE, M.D.
Washington, D.C.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

There are no citations for this item

View Options

View options

PDF/ePub

View PDF/ePub

Get Access

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share